LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $2,002,104.00 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 18,600 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $107.64, for a total transaction of $2,002,104.00. Following the completion of the sale, the chief executive officer directly owned 1,457,900 shares of the company’s stock, valued at $156,928,356. This represents a 1.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $98.17 on Thursday. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $2.24 billion, a P/E ratio of 36.23, a P/E/G ratio of 2.70 and a beta of 0.60. LeMaitre Vascular, Inc. has a 12-month low of $78.35 and a 12-month high of $118.01. The firm has a 50-day moving average price of $109.69 and a two-hundred day moving average price of $94.82.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s payout ratio is currently 36.90%.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Sound Income Strategies LLC increased its position in LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 183 shares during the period. Cornerstone Planning Group LLC increased its position in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 283 shares during the period. Catalyst Capital Advisors LLC acquired a new position in LeMaitre Vascular in the 1st quarter valued at approximately $32,000. MAI Capital Management acquired a new position in LeMaitre Vascular in the 3rd quarter valued at approximately $38,000. Finally, First Horizon Corp acquired a new position in LeMaitre Vascular in the 3rd quarter valued at approximately $39,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent research reports. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 6th. Barrington Research upped their price target on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Roth Mkm restated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.